EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Integration of RASSF1A and TSPYL5 methylation and AFP protein as plasma biomarker for hepatocellular carcinoma diagnosis

Haiyan Chen, Yingmin Luo, Linhong Li, Fei Xu, Xiaohuan Lai, Jinlong Li, Xiaomo Li, Wenjie Song, Yang Liu, Dengke Bao, Jiayun Liu, Guanlin Zhou und 1 weitere

Journal of Cancer Research and Clinical Oncology · 2025

DOI: 10.1007/s00432-025-06367-8 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Cancer Research and Clinical Oncology, 2025. Verfasst von Haiyan Chen und 12 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Genomics and Precision Medicine, Department of Technology in Medicine, Gannan Medical University, Ganzhou, China. Hauptthemen laut MEDLINE: Carcinoma, Hepatocellular, Liver Neoplasms, Tumor Suppressor Proteins, DNA Methylation. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 54 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Early detection of hepatocellular carcinoma (HCC) represents a significant clinical challenge due to the lack of effective biomarkers. Previous studies have revealed abnormal hypermethylation of RASSF1A and TSPYL5 in HCC tissues, prompting further investigation into their utility as potential biomarkers for HCC diagnosis. In this study, we explored the clinical value of RASSF1A/TSPYL5 methylation alone and in combination with AFP protein as diagnostic biomarkers for early HCC detection. METHODS: Bioinformatics analysis using MethSurv, LinkedOmics, and Wanderer was conducted to assess the methylation levels of RASSF1A and TSPYL5 in HCC tissue samples from the public database. The methylation status of these two genes was validated in cell lines and plasma samples from HCC patients. Furthermore, the ARTHCC model, comprising the measurement of RASSF1A and TSPYL5 methylation and AFP protein, was developed and validated using plasma samples from HCC patients. RESULTS: Our comprehensive bioinformatic analysis revealed that TSPYL5 CpG sites were hypermethylated in HCC tissue samples, particularly among CpG island and shore regions. Approximately 40% of CpG sites of RASSF1A also exhibited hypermethylation. The hypermethylation status of TSPYL5 may be associated with portal vein tumor thrombus (PVTT) in HCC patients. Combining analysis of RASSF1A and TSPYL5 methylation levels with AFP protein, the ARTHCC model demonstrates superior sensitivity and specificity for detecting HCC in both the discovery and validation cohorts. Notably, the ARTHCC model consistently exhibited robust performance across different subgroups. CONCLUSIONS: This study provides compelling evidence that the combination of RASSF1A/TSPYL5 methylation and AFP protein is a promising biomarker panel for the early detection of HCC. The ARTHCC model demonstrates remarkable sensitivity and specificity, outperforming AFP.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, HepatocellularLiver NeoplasmsTumor Suppressor ProteinsDNA MethylationBiomarkers, Tumoralpha-FetoproteinsThrombospondinsHumansMaleFemaleMiddle AgedCpG IslandsComputational Biology

Stichwörter der Autor:innen

RASSF1ATSPYL5AFPDNA methylationEarly detectionHepatocellular carcinomaQuantitative methylation-specific PCR

Substanzen

RASSF1 protein, humanTumor Suppressor ProteinsBiomarkers, Tumoralpha-FetoproteinsAFP protein, humanThrombospondins

Autor:innen und Institutionen

  • Institute of Genomics and Precision Medicine, Department of Technology in Medicine, Gannan Medical University, Ganzhou, China.
  • China Medical University, Shenyang, China.
  • Institute of Hepatology, Department of Hepatology, The Affiliated Fifth People's Hospital of Ganzhou, Gannan Medical University, Ganzhou, China.
  • Research and Development Division, Oriomics Biotech Inc, Hangzhou, China.
  • Department of Hepatobiliary Surgery, Xijing Hospital, Fourth Military Medical University, Xi'an, China.
  • State Key Laboratory of Holistic Integrative Management of Gastrointestinal Cancers and Department of Physiology and Pathophysiology, Fourth Military Medical University, Xi'an, China.

Zitieren

APA

Chen, H., Luo, Y., Li, L., Xu, F., Lai, X., Li, J., Li, X., Song, W., Liu, Y., Bao, D., Liu, J., Zhou, G., & Wan, S. (2025). Integration of RASSF1A and TSPYL5 methylation and AFP protein as plasma biomarker for hepatocellular carcinoma diagnosis. Journal of Cancer Research and Clinical Oncology. https://doi.org/10.1007/s00432-025-06367-8

Vancouver

Chen H, Luo Y, Li L, Xu F, Lai X, Li J, et al. Integration of RASSF1A and TSPYL5 methylation and AFP protein as plasma biomarker for hepatocellular carcinoma diagnosis. Journal of Cancer Research and Clinical Oncology. 2025. doi:10.1007/s00432-025-06367-8

BibTeX
@article{Chen2025,
  author = {Chen, Haiyan and Luo, Yingmin and Li, Linhong and Xu, Fei and Lai, Xiaohuan and Li, Jinlong and Li, Xiaomo and Song, Wenjie and Liu, Yang and Bao, Dengke and Liu, Jiayun and Zhou, Guanlin and Wan, Shaogui},
  title = {Integration of RASSF1A and TSPYL5 methylation and AFP protein as plasma biomarker for hepatocellular carcinoma diagnosis},
  journal = {Journal of Cancer Research and Clinical Oncology},
  year = {2025},
  doi = {10.1007/s00432-025-06367-8}
}
Kostenlos starten →